CN105079076A - Pharmaceutical composition for treating growth hormone insufficiency syndrome in adults - Google Patents
Pharmaceutical composition for treating growth hormone insufficiency syndrome in adults Download PDFInfo
- Publication number
- CN105079076A CN105079076A CN201410200379.0A CN201410200379A CN105079076A CN 105079076 A CN105079076 A CN 105079076A CN 201410200379 A CN201410200379 A CN 201410200379A CN 105079076 A CN105079076 A CN 105079076A
- Authority
- CN
- China
- Prior art keywords
- medical composition
- growth hormone
- powder
- radix
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to a pharmaceutical composition for treating growth hormone insufficiency syndrome in adults. The pharmaceutical composition mainly comprises Rhodiola crenulata extract and Paecilomyces hepiala Chen et Dai mycelia powder.
Description
Technical field
The present invention is about a kind of medical composition being used for the treatment of the not enough syndrome of Adult GH.
Background technology
The synthetic hormone (anabolichormone) that growth hormone (GH) is human secretory, has the functions such as the repairing promoting muscular strength development, muscle growth and protein synthesis and promote wounded tissue.Use growth hormone treat the growth hormone deficiency of adult clinically, and use growth hormone therapy show and can reduce fat, increase muscle strength and improve sclerotin.In addition, the secretory volume of human growth hormone increases along with the age and lowers, and therefore, also has with somatotropin prolonged aging correlational study.
Adult growth hormone deficiency mainly causes body weight increases, lipotrophy, muscle minimizings, bone-loss, motor capacity is not enough, overall energy low, cardiovascular disease increases, the lost of life, immune depression, xerosis cutis, cold-resistant, metabolism reduces, have a sleepless night, HDL-C lowly, the symptom such as attention cannot concentrate, forgetful and emotional instability, be generally referred to as Adult GH's deficiency syndrome.
So, the side effect that long term injections growth hormone is possible comprises: arthroncus, arthralgia, Carpel Tunnel Syndrome, and the risk having increase diabetes.
The invention provides a kind of medical composition, it can promote that human growth hormone secretes, and for the manufacture for the treatment of the medicament of the not enough syndrome of Adult GH.This medical composition mainly comprises Radix Rhodiolae and Cordyceps two kinds of compositions, known Radix Rhodiolae and Cordyceps two kinds of Chinese herbal medicine for having allaying tiredness, prevent high mountain disease, anti-inflammatory and reduce the effects such as free radical.
Summary of the invention
The object of this invention is to provide one and be used for the treatment of the not enough syndrome medical composition of Adult GH, comprise Radix Rhodiolae and Cordyceps.In specific words, medical composition of the present invention comprises: Radix Rhodiolae (Rhodiolacrenulata) extract of 50 to 95 % by weight, and the Paecilomyces hepiali Chen et Dai Mycelia of 5 to 50 % by weight (PaecilomyceshepialaChenetDaimycelia) powder.
Medical composition of the present invention can comprise Herba Cistanches (Cistanchetubulosa), Radix Et Caulis Acanthopanacis Senticosi (SiberianGinseng), taurine (Taurine) and Radix Ginseng further and concentrate powder (Ginseng); Further can comprise pharmaceutically acceptable excipient, this excipient can be selected from one of magnesium stearate and silicon dioxide or many persons.
Another object of the present invention is to provide and a kind ofly utilizes above-mentioned medical composition manufacture to treat the not enough medicament of syndrome of Adult GH or the purposes of health food.
Another object of the present invention is to provide a kind of purposes utilizing above-mentioned medical composition manufacture to promote the medicament that human growth hormone secretes or health food.
Medicament of the present invention and health food are oral dosage form, and it can be lozenge, capsule or powder.
Accompanying drawing explanation
Fig. 1 is the flow chart preparing Radix Rhodiolae extract of the present invention.
Fig. 2 is the flow chart preparing Paecilomyces hepiali Chen et Dai Mycelia powder of the present invention.
Fig. 3 shows rat growth hormone concentration change situation in (Post-ex) and convalescent blood after (Pre-ex), motion before motion.
Detailed description of the invention
Prepare medical composition of the present invention
Medical composition of the present invention mainly comprises Radix Rhodiolae extract and Paecilomyces hepiali Chen et Dai Mycelia powder.The preparation of this Radix Rhodiolae extract with reference to the flow chart of Fig. 1, by Radix Rhodiolae greenwood through pulverizing, extraction, after concentrated and lyophilization, then through levigation and sieve to make.Through further check analysis, in this Radix Rhodiolae extract containing have an appointment 1% rhodioside (salidroside) index components.Separately, the preparation of this Paecilomyces hepiali Chen et Dai Mycelia powder with reference to the flow chart of Fig. 2, by peacilomyce hepiahi bacterium strain through cultivating and fermentation, gained mycelium again through freezing or bake drying, grind and sieve to make.In addition, the medical composition of the present invention further comprises Herba Cistanches, taurine and Radix Ginseng and concentrates powder; And further can comprise pharmaceutically acceptable excipient, this excipient can be selected from one of magnesium stearate and silicon dioxide or many persons.Medical composition of the present invention comprises the Paecilomyces hepiali Chen et Dai Mycelia powder of 50 to 95 % by weight Radix Rhodiolae extracts and 5 to 50 % by weight.Medical composition of the present invention is preferably makes lozenge, such as, in the 600mg lozenge made with medical composition of the present invention, comprises the Radix Rhodiolae extract of 420mg and the Paecilomyces hepiali Chen et Dai Mycelia powder of 180mg.
The test of medical composition growth promoting effects hormone secretion of the present invention
According to research, after high strength or prolonged exercise, the change of hormonal system and regulation and control motor fitness phenomenon will be brought out.Therefore, by hormone concentration change after measurement motion, the effect of medical composition growth promoting effects hormone secretion of the present invention is analyzed.
Use SpragueDawley (SD) rat of 40 body weight about 250 grams, be divided into according to body weight matching method: placebo group (control group, n=10), dosage is 124mg/kg (n=10), 248mg/kg (n=10) and 744mg/kg (n=10).The every day same time gives the medical composition of the present invention of a relative body weight dosage in supply bobbin mode, continuous feeding 10 days.This test use medical composition to comprise each composition and content as shown in the table:
| Composition | Mg/ ingot | ％ |
| Radix Rhodiolae extract | 480 | 80.0 |
| Herba Cistanches | 42 | 7.0 |
| Paecilomyces hepiali Chen et Dai Mycelia powder | 36 | 6.0 |
| Radix Et Caulis Acanthopanacis Senticosi | 18 | 3.0 |
| Taurine | 18 | 3.0 |
| Radix Ginseng concentrates powder | 6 | 1.0 |
| Subtotal | 600 | 100.0 |
Measure (Pre-ex) before moving after (baseline), continuous seven days feedings before feeding respectively, extremely exhaustion rear (Post-ex), the tail challenging four time points of rear convalescent period that moves take growth hormone concentration change in blood sample to implement single motion challenge in treadmill mode every other day.
Get 400 μ l blood plasma after blood sample is centrifugal, use growth hormone reagent (Millipore, Billerica, USA) to analyze growth hormone concentration with TECANGeniosELISAanalyzer (Salzburg, Austria).With the variable of two factor repeated-measures analysis mode (Two-wayanalysisofvariancewithrepeatedmeasures) more each time points, recycling independent sample t-test compares the difference measuring variable between various dose group.Numerical value presentation mode is average ± standard error (mean ± SE), notable level Wei α≤0.05.
The result of growth hormone change refers to Fig. 3, after within continuous seven days, taking 124mg/kg dosage, growth hormone concentration before motion in (Pre-ex) blood is significantly higher than control group and reaches 12 times, the concentration no significant difference of (Post-ex) four groups after the challenge of single Exhaustive exercise; So, in convalescent 124mg/kg dosage group higher than control group 6 times; 248mg/kg dosage group is higher than control group 10 times; And 744mg/kg dosage group is higher than control group 5 times.Show medical composition of the present invention and can effectively improve growth hormone concentration, the secretion of growth promoting effects hormone, the associated conditions for growth hormone deficiency has therapeutic effect.
Above-mentioned preferred embodiment is only and illustrates, not for limiting the present invention, be familiar with the art person according to above-mentioned explanation make different changes, all belong to scope of the present invention.
Claims (7)
1. be used for the treatment of the not enough syndrome medical composition of Adult GH, comprise the Radix Rhodiolae extract of 50 to 95 % by weight, and the Paecilomyces hepiali Chen et Dai Mycelia powder of 5 to 50 % by weight.
2. medical composition as claimed in claim 1, it comprises Herba Cistanches, Radix Et Caulis Acanthopanacis Senticosi, taurine and Radix Ginseng further and concentrates powder.
3. medical composition as claimed in claim 1 or 2, it comprises pharmaceutically acceptable excipient further, and it one of to be selected from magnesium stearate and silicon dioxide or many persons.
4. medical composition as claimed in claim 1, wherein, this Radix Rhodiolae extract containing have an appointment 1% rhodioside.
5. a purposes for the medical composition according to any one of Claims 1 to 4, its medicament for the manufacture of the not enough syndrome for the treatment of Adult GH or health food.
6. a purposes for the medical composition according to any one of Claims 1 to 4, it is for the manufacture of the medicament or the health food that promote human growth hormone's secretion.
7. the purposes as described in claim 5 or 6, wherein, this medicament or health food are the oral dosage form of lozenge, capsule or powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410200379.0A CN105079076A (en) | 2014-05-13 | 2014-05-13 | Pharmaceutical composition for treating growth hormone insufficiency syndrome in adults |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410200379.0A CN105079076A (en) | 2014-05-13 | 2014-05-13 | Pharmaceutical composition for treating growth hormone insufficiency syndrome in adults |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105079076A true CN105079076A (en) | 2015-11-25 |
Family
ID=54561007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410200379.0A Pending CN105079076A (en) | 2014-05-13 | 2014-05-13 | Pharmaceutical composition for treating growth hormone insufficiency syndrome in adults |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105079076A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1480206A (en) * | 2002-09-02 | 2004-03-10 | 成都浦泓生物科技开发有限公司 | Combination of gadol and Chinese caterpillar fungus as well as preparing method |
| US20080089946A1 (en) * | 2005-11-10 | 2008-04-17 | Olalde Rangel Jose A | Synergistic Phytoceutical Compositions |
| CN101721613A (en) * | 2008-10-14 | 2010-06-09 | 北京因科瑞斯医药科技有限公司 | Composition for enhancing constitution and preparation method thereof |
-
2014
- 2014-05-13 CN CN201410200379.0A patent/CN105079076A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1480206A (en) * | 2002-09-02 | 2004-03-10 | 成都浦泓生物科技开发有限公司 | Combination of gadol and Chinese caterpillar fungus as well as preparing method |
| US20080089946A1 (en) * | 2005-11-10 | 2008-04-17 | Olalde Rangel Jose A | Synergistic Phytoceutical Compositions |
| CN101721613A (en) * | 2008-10-14 | 2010-06-09 | 北京因科瑞斯医药科技有限公司 | Composition for enhancing constitution and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9775868B2 (en) | Traditional Chinese medicine combination for regulating immune function and preparation method therefor | |
| CN101357136B (en) | Composition of traditional Chinese medicine effective constituent for preventing and treating diseased associated with cerebral ischemia injury | |
| CN101711810B (en) | Preparation used for improving sleep and enhancing immunity | |
| CN111035649B (en) | NMN + GLP compound nutritional supplement and preparation method and application thereof | |
| CN104257696A (en) | Yeast powder for reducing and stabilizing blood sugar as well as preparation method and application of yeast powder | |
| CN105341893A (en) | Composition for assisting in reducing blood glucose and application | |
| CN101380346A (en) | Traditional Chinese composition for treating tumor and production method thereof | |
| CN107260963A (en) | The method that treatment hypertension drug is prepared as main material using dendrobium candidum and radish seed | |
| Ulbricht et al. | An evidence-based systematic review of active hexose correlated compound (AHCC) by the Natural Standard Research Collaboration | |
| CN102657730A (en) | Rhodiola rosea buccal preparations for resisting altitude reaction | |
| TWI678211B (en) | Uses of cistanche tubulosa extract and isoacteoside in protecting muscles | |
| CN105079076A (en) | Pharmaceutical composition for treating growth hormone insufficiency syndrome in adults | |
| US10383904B2 (en) | Composition for improving health and quality of life of women containing ginseng berry extract | |
| CN104546987A (en) | Application of gynostemma pentaphyllum total saponins to prevention and cure of hyperuricemia | |
| CN105616633A (en) | Preparation method of traditional Chinese medicine composition for treating leukopenia after chemotherapy | |
| TWI626944B (en) | Pharmaceutical composition for the treatment of adult growth hormone deficiency syndrome | |
| WO2010037255A1 (en) | The usage of ginseng and gynostemma pentaphyllum compound preparation in manufacture of medicaments with the effects of lipid regulation and blood-sugar regulation | |
| CN102327304B (en) | Drug for preventing and controlling chronic mountain sickness and preparation method thereof | |
| CN104740428B (en) | A kind of compound tonifying blood containing red skin of peanut pharmaceutical preparation and its application and detection method | |
| CN104013680A (en) | Extractive for preparing astragalus membranaceus-ligustrum healthy-qi-reinforcing preparation | |
| CN104983759A (en) | Traditional Chinese medicine composition treating diabetic nephropathy and preparing method thereof | |
| CN104546966B (en) | A kind of antitumor Chinese with Immunologic Functions | |
| CN103860761A (en) | Pharmaceutical composition with effects of improving immunity and resisting fatigue as well as preparation method and application of pharmaceutical composition | |
| CN116688058B (en) | Li medicine for impotence, preparation method and application thereof | |
| CN107927745B (en) | A Chinese medicinal health food composition, and its preparation method and preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20151125 |